A Phase 2, Open-label, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Oral Tazemetostat for the Treatment of Adult Participants Age 18 and Over With Relapsed/Refractory Follicular Lymphoma Lacking the EZH2 Gain-of-Function (GOF) Mutation

The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an "EZH2 gain-of-function" genetic mutation. Follicular lymphoma is a blood cancer. It affects white blood cells called lymphocytes. White blood cells normally help to fight infections, but when you have follicular lymphoma, the blood cells can form tumours in your body. 'Relapsed/refractory' follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment.
Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the "EZH2" mutation who have no satisfactory alternative treatment options.
This study is being conducted to better understand the effectiveness in patients whose tumours do not have an "EZH2 gain-of-function" genetic mutation and who previously received therapies commonly used in the U.S. in your body.
'Relapsed/refractory' follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment.
Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the "EZH2 gain-of-function" mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an "EZH2" genetic mutation and who previously received therapies commonly used in the U.S.
In this study, all participants will receive the study drug. It will be taken by mouth (orally), as a tablet, twice daily. The sizes and number of tumours according to scan results will be collected as well as results of safety tests (such as physical examinations and laboratory tests).
The study consists of 4 periods:
* Screening period may take up to 4 weeks and require at least 1 visit.
* Treatment period will require 2 visits for each of the first 2 months, followed by 1 visit every month for the remainder of the first 12 months, followed by 1 visit every 3 months (except for women of childbearing potential [WOCBP], who will continue to have a pregnancy testing every month) until unacceptable toxicity, disease progression, or the start of new systemic anticancer therapy, whichever is first.
* Safety follow-up period will last for 1 month after the last dose of tazemetostat, and it will end with 1 visit or telephone call.
* Long-term follow-up period is only for participants who stop taking tazemetostat while their disease continues to respond; this period will last until disease progression, start of new cancer treatment, or death from any cause, whichever is first, and will require a visit every 3 months.
Tazemetostat will be provided to participants who tolerate it for as long as their disease does not progress.
Participants may be transferred to another study or program after about 2 years for continued treatment with tazemetostat or for long-term follow-up. Patients may withdraw consent to participate at any time.

开始日期2025-09-02

申办/合作机构

Epizyme, Inc.

[+1]

NCT06824701

/ Not yet recruiting临床1期IIT

A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas

The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

开始日期2025-06-01

申办/合作机构

University of Utah

[+1]

NCT06575686

/ Recruiting临床2期IIT

A Phase 2 Study of Epcoritamab Plus Tazemetostat for Treatment of Relapsed/Refractory Follicular Lymphoma

This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens on the surface of cancer cells that may help the body's immune system attack the cancer and may interfere with the ability of the cancer cells to grow and spread. Tazemetostat, a EZH2 inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving epcoritamab and tazemetostat may be safe, tolerable and/or effective in treating patients with relapsed or refractory grade I-IIIa follicular lymphoma.

开始日期2025-03-11

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与氢溴酸他泽司他相关的临床结果

登录后查看更多信息

100 项与氢溴酸他泽司他相关的转化医学

登录后查看更多信息

100 项与氢溴酸他泽司他相关的专利（医药）

登录后查看更多信息

463

项与氢溴酸他泽司他相关的文献（医药）

2025-12-01·FUNCTIONAL & INTEGRATIVE GENOMICS

Polycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistance

Review

作者: Tabari, Mohammad Amin Khazeei ; Khan, Haroon ; Javan, Alireza ; Larsen, Danaé S ; Rezaee, Aryan ; Heidari, Mohammad Mahdi ; Sanaye, Pantea Majma ; Hadipour, Mahboube ; Goleij, Pouya ; Daglia, Maria

Polycomb Repressive Complex 2 (PRC2) is a central regulator of gene expression via the trimethylation of histone H3 on lysine 27. This epigenetic modification plays a crucial role in maintaining cell identity and controlling differentiation, while its dysregulation is closely linked to cancer progression. PRC2 silences tumor suppressor genes, promoting cell proliferation, metastasis, epithelial-mesenchymal transition, and cancer stem cell plasticity. Enhancement of zeste homolog 2 (EZH2) overexpression or gain-of-function mutations have been observed in several cancers, including lymphoma, breast, and prostate cancers, driving aggressive tumor behavior and drug resistance. In addition to EZH2, other PRC2 components, such as embryonic ectoderm development (EED) and suppressor of zeste 12, are essential for complex stability and function. EED, in particular, enhances EZH2 activity and has emerged as a therapeutic target. Inhibitors like MAK683 and EED226 disrupt EED's ability to maintain PRC2 activity, thereby reducing H3K27me3 levels and reactivating tumor suppressor genes. Valemetostat, a dual inhibitor of both EZH2 and EED, has shown promising results in aggressive cancers like diffuse large B-cell lymphoma and small-cell lung cancer, underlining the therapeutic potential of targeting multiple PRC2 components. PRC2's role extends beyond gene repression, as it contributes to metabolic reprogramming in tumors, regulating glycolysis and lipid synthesis to fuel cancer growth. Furthermore, PRC2 is implicated in chemoresistance, particularly by modulating DNA damage response and immune evasion. Tazemetostat, a selective EZH2 inhibitor, has demonstrated significant clinical efficacy in EZH2-mutant cancers, such as non-Hodgkin lymphomas and epithelioid sarcoma. However, the compensatory function of enhancer of zeste homolog 1 (EZH1) in some cancers requires dual inhibition strategies, as seen with agents like UNC1999 and Tulmimetostat, which target both EZH1 and EZH2. Given PRC2's multifaceted role in cancer biology, its inhibition represents a promising avenue for therapeutic intervention. The continued development of PRC2 inhibitors and exploration of their use in combination with standard chemotherapy or immunotherapy has great potential for improving patient outcomes in cancers driven by PRC2 dysregulation.

2025-08-01·BRAIN BEHAVIOR AND IMMUNITY

EZH2-mediated suppression of TIMP1 in spinal GABAergic interneurons drives microglial activation via MMP-9-TLR2/4-NLRP3 signaling in neuropathic pain

Article

作者: Pan, Yinbing ; Wu, Xuefeng ; Wu, Xudong ; Liu, Wentao ; Hu, Fan ; Guo, Haiyue ; Yang, Shuo ; Jiang, Chun-Yi ; Wan, Li

Effective management of neuropathic pain remains a significant challenge due to the limited understanding of its underlying mechanisms. We found that the FDA-approved enhancer of zeste homolog 2 (EZH2) inhibitor, EPZ6438, can prevent the development of neuropathic pain caused by chronic constriction injury (CCI). Therefore, we utilized EPZ6438 as a probe to investigate the molecular events involved in the early stage of neuropathic pain. RNA-seq analysis reveals that EPZ6438 significantly upregulates Timp1 transcription in the spinal cord of mice. As a specific endogenous inhibitor of MMP-9, tissue inhibitor of metalloproteinase 1 (TIMP1) levels significantly decrease in the cerebrospinal fluid of both neuropathic pain patients and the CCI rat models. Importantly, intrathecal administration of mouse recombinant TIMP1 protein (rmTIMP1) reverses CCI-induced mechanical and thermal hyperalgesia. Mechanistically, substance P released from primary sensory neurons suppresses TIMP1 in spinal GABAergic interneurons by elevating EZH2 expression, which enhances H3K27me3 enrichment at the Timp1 promoter. Blocking spinal NK1R effectively prevents the downregulation of TIMP1 and alleviates CCI-induced hyperalgesia. The imbalance between TIMP1 and MMP-9 leads to NLRP3 activation in spinal microglia and increases IL-1β maturation via TLR2/4 pathway. TIMP1 injection eliminates MMP-9-induced NLRP3 activation and blocks hyperalgesia, suggesting that TIMP1 is a critical gatekeeper in preventing neuroinflammation during neuropathic pain development.

2025-05-22·JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines

Article

作者: Liu, Li ; Liu, Xinqiao ; Fang, Wei ; Shi, Qiongyu ; Zhang, Ying ; Wang, Yuanxiang ; Zhang, Yi ; Huang, Yuting ; Yang, Hong ; Huang, Xun

Targeted covalent inhibition is a promising strategy to address the high dose and acquired drug resistance issues of the first-generation EZH2 noncovalent inhibitors. Recently we have reported a new generation of highly potent EZH2 covalent inhibitors, but further optimization to enhance aqueous solubility is required. Here, we described the systematic optimization of EPZ-6438 by preserving the aqueous groups, resulting in the identification of a highly potent and selective EZH2 covalent inhibitor 13, which displayed nanomolar potency in biochemical and cellular assays. Moreover, SAM competition experiments preliminarily confirmed that 13 was noncompetitive with SAM, leading to the remarkable reduction of the H3K27Me3 marker. In addition, 13 exhibited superior cell growth inhibition in the EZH2 mutant cancer cell lines. The discovery of 13 holds promise for the development of highly potent EZH2 covalent inhibitors.

172

项与氢溴酸他泽司他相关的新闻（医药）

2025-05-20

·CPHI制药在线

国产势力崛起：信诺维、恒瑞医药等如何领跑EZH2抑制剂全球竞速？

关注并星标CPHI制药在线5月19日，苏州信诺维医药科技股份有限公司的1类新药XNW5004片被CDE拟纳入突破性治疗品种，拟用于治疗既往接受过至少3线全身系统治疗的复发或难治性滤泡性淋巴瘤（EZH2野生型）。 XNW5004是信诺维医药自主研发的一种底物竞争性、选择性小分子EZH2抑制剂，在临床前体外、体内多个实体瘤模型上展示出良好的抗肿瘤活性，且安全性较好。 XNW5004被开发用于治疗外周T细胞淋巴瘤等淋巴瘤和前列腺癌等晚期或转移性实体瘤，其中复发或难治性外周 T 细胞淋巴瘤（PTCL）适应症于2024年9月被CDE授予突破性疗法认定。目前，XNW5004对照西达本胺治疗复发或难治性PTCL的随机、双盲、多中心III期临床试验正在进行中。针对前列腺癌，临床数据显示XNW5004联合恩扎卢胺可显著延长患者的无进展生存期（PFS）。此次XNW5004的复发或难治性滤泡性淋巴瘤适应症被CDE授予突破性治疗认定，将加速该适应症的开发进程。而已公布的XNW5004治疗复发或难治性非霍奇金淋巴瘤（NHL）的1期临床试验结果显示：XNW5004针对EZH2野生型滤泡性淋巴瘤患者的ORR为40%，DCR为100%，中位PFS和中位DOR均未达到。 EZH2抑制剂进展，SHR2554已报产，系首款国产创新 EZH2是目前非常热门的表观遗传学靶点之一，其是多梳抑制复合物2（PRC2）的催化活性亚单位，主要通过甲基化组蛋白H3第27位赖氨酸（H3K27me3）来抑制靶基因的转录，参与调控细胞周期、细胞衰老、细胞分化及肿瘤发生等病理生理过程。 EZH2最早发现在激素难治性转移性前列腺癌中高表达，后来发现其在乳腺癌、胃癌、结直肠癌、非霍奇金淋巴瘤等多种肿瘤中高表达，且其高表达与这些肿瘤的不良预后和肿瘤侵袭性相关。在血液肿瘤中，研究发现EZH2可通过抑制抑癌基因的表达与转录来对血液肿瘤的增殖和侵袭转移产生影响。而且，EZH2还可影响肿瘤免疫，其一方面可对CD4+、CD8+T及NK细胞的分化产生影响，同时调控调节性T细胞（Tregs）的功能表型；另一方面，研究显示EZH2对肿瘤微环境的抑制和重塑具有多重效应，通过抑制EZH2的表达，可以促进CD8+T细胞的功能并向肿瘤微环境转移，还可减轻Tregs对肿瘤微环境的影响，增加肿瘤微环境中抗原的表达、处理和呈递。据不完全统计，目前全球监管机构已批准2款EZH2抑制剂，即第一三共的伐美妥司他（Valemetostat，Ezharmia）和Epizyme/和黄医药的他泽司他（Tazemetostat，Tazverik）。其中伐美妥司他是全球首款获批的EZH1/2双重抑制剂,在日本获批治疗复发或难治性成人T细胞白血病/淋巴瘤 (ATL)和复发或难治性成人PTCL。他泽司他是全球首款获批的EZH2抑制剂，在美国获批多个适应症：16岁及以上不能完全切除的转移性或局部晚期上皮样肉瘤；至少接受两次全身治疗、EZH2突变阳性的成人复发或难治性FL；没有令人满意的替代治疗方案的成人R/R FL。2025年3月，他泽司他在国内获批，用于治疗复发或难治性FL。此外，目前全球还有多款在研EZH2抑制剂。恒瑞医药开发的EZH2抑制剂SHR2554进展较快，其治疗既往接受过至少1线系统性治疗的复发或难治PTCL的适应症上市申请正在国内接受优先审查。 SHR2554是一款新型、高效、选择性口服EZH2抑制剂，可选择性强效抑制野生型和突变型EZH2酶活性。已公布的首个人体临床试验结果显示，SHR2554每天2次350mg给药安全性可接受，对复发难治FL、PTCL和经典霍奇金淋巴瘤均显示出良好的抗肿瘤活性。而针对复发或难治PTCL，已公布的SHR2554针对复发/难治成熟淋巴瘤的1期临床研究中复发/难治性外周T细胞淋巴瘤（PTCL）部分的分析结果显示：在17例患者中ORR达61%，估计的mDOR为12.3个月，mPFS为11.1个月，12个月总生存率为92%。辉瑞的PF-06821497（mevrometostat）进展也较快，目前正在开展两项3期临床试验MEVPRO-1和MEVPRO-2，其中MEVPRO-1旨在评估PF-06821497联合恩扎卢胺对比恩扎卢胺或多西他赛治疗既往接受过醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌疗效和安全性，MEVPRO-2研究旨在评估PF-06821497联合恩扎卢胺治疗未经阿比特龙治疗的转移性去势抵抗性前列腺癌的疗效和安全性。已公布的1期临床试验结果显示，PF-06821497联合恩扎卢胺对经治转移性去势抵抗性前列腺癌（mCRPC）表现出可喜的抗癌活性，PF-06821497联合恩扎卢胺治疗既往经阿比特龙治疗的mCRPC的中位放射学无进展生存期（rPFS）为17.1个月，相比于历史数据（rPFS为4.8个月）有显著获益。海和药物的HH2853处于1/2期临床。该药是一款强效、高选择性EZH1/2小分子抑制剂。临床前研究显示：HH2853能强效抑制细胞内的整体H3K27me3水平，在PTCL、含有EZH2突变的弥漫性大B细胞淋巴瘤（DLBCL）以及含有SWI/SNF复合物亚基突变的多种实体瘤模型中均显示强效的体内外抗肿瘤活性，且同等剂量下HH2853的抗肿瘤活性与他泽司他相比更优。1期临床试验结果显示：HH2853具有良好的安全性和优异的药代动力学特征，在多瘤种中展示出初步疗效。中科拓苒的TR115、诺华的AXT1003等处于1期临床。其中TR115是一款新一代高活性高选择性EZH2抑制剂，细胞水平的研究结果显示其在表观遗传学靶点间具有良好的选择性，对EZH2野生型及EZH2 Y641F等突变均具有强烈的抑制作用。临床前研究结果显示：TR115能显著的抑制相关肿瘤细胞的增殖及肿瘤的生长，有望成为治疗非霍奇金性淋巴瘤和晚期恶性实体瘤等的新一代的靶向治疗药物。而AXT1003是一款EZH2靶向蛋白降解剂，其治疗晚期恶性肿瘤的1期临床试验正在进行中。总结作为表观遗传关键靶点，EZH2通过甲基化组蛋白H3K27调控基因转录，其异常表达与淋巴瘤、前列腺癌等多种肿瘤的恶性进展密切相关。目前全球已批准2款，恒瑞医药的SHR2554已经报产，辉瑞的PF-06821497和信诺维的XNW5004进展也相对较快，已进入3期临床。然而，目前EZH2抑制剂的发展仍有其局限性，适应症主要集中在淋巴瘤。未来，联合治疗（联合靶向药、化疗药等）、生物标志物开发（预测疗效与耐药）、新型抑制剂研发（克服耐药）以及拓展适应症（非肿瘤疾病领域）将成为EZH2研究的主要方向，有望为相关疾病治疗开辟新局面。END【企业推荐】智药研习社直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

突破性疗法临床1期ASH会议临床2期临床申请

2025-05-12

·ioncology

18-ICML·抢先看丨汇聚中国风采！第18届国际恶性淋巴瘤会议17项口头报告及30项壁报全景呈现

由瑞士肿瘤研究所基金会（IOR）主办的第18届国际恶性淋巴瘤会议（18-ICML）将于2025年6月17日至21日在瑞士卢加诺会议中心（Palazzo dei Congressi）召开。作为全球血液肿瘤学领域最具影响力的两年一度的学术盛会，本届会议预计汇聚来自全球的千余名血液学家、临床肿瘤学家、放射肿瘤学家、儿科医生、病理学家及淋巴瘤研究领域的前沿学者，共同探讨疾病机制、转化医学进展及临床诊疗创新。在本次盛会中，中国学者以丰富的学术成果为会议增光添彩，共呈现17项口头报告及30项壁报展示（截至2025年5月12日）。《肿瘤瞭望-血液时讯》特此系统梳理研究成果，旨在为临床医师及科研工作者提供学术风向标，助力我国淋巴瘤诊疗水平的提升。口头报告（ORAL）*汇报时间均为当地时间1淋巴瘤放射治疗研讨会LYMPHOMA RADIOTHERAPY WORKSHOP中文题目：现今应该采用哪种全身治疗方案？英文题目：Which systemic regimen should be used today?发言人：中山大学附属肿瘤医院蔡清清教授时间：6.17 16:15地点：Cinema Corso中文题目：现代系统性治疗背景下早期阶段的放射剂量与照射体积英文题目：Radiation doses and volumes in early stages with modern systemic therapy发言人：Shunan Qi（北京）时间：6.17 16:30地点：Cinema Corso2聚焦专场-进行中的临床试验“FOCUS ON…” SESSIONS-ONGOING TRIALS中文题目：GUIDANCE-02：一项关于遗传亚型指导的免疫化疗在弥漫大B细胞淋巴瘤中的多中心随机III期研究英文题目：GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma摘要号：OT5发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.18 17:40地点：Cinema Corso3儿童淋巴瘤PEDIATRIC LYMPHOMAS中文题目：中国T细胞淋巴母细胞淋巴瘤儿科患者中融合基因的发生频率及其临床影响英文题目：Frequency of fusion genes and their clinical impacts in Chinese pediatric patients with T cell lymphoblastic lymphoma摘要号：36发言人：高博医学（血液病）北京研究中心北京高博博仁医院医疗张永红教授时间：6.19 15:55地点：Auditorium, West Campus USI中文题目：53例复发或难治性儿童ALK阳性间变性大细胞淋巴瘤的临床分析英文题目：Clinical analysis of 53 cases of relapsed or refractory childhood ALK + anaplastic large cell lymphoma摘要号：38发言人：高博医学（血液病）北京研究中心王凯教授时间：6.19 16:15地点：Auditorium, West Campus USI4套细胞淋巴瘤MANTLE CELL LYMPHOMA中文题目：奥布替尼、来那度胺联合利妥昔单抗作为套细胞淋巴瘤一线治疗的新型三联方案：POLARIS多中心II期研究的最终结果英文题目：Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of POLARIS Multicenter Phase II Study摘要号：48发言人：天津医科大学肿瘤医院宋拯教授时间：6.19 16:15地点：Room A.bradcast in Ginema Corso5早期临床试验EARLY CLINICAL TRIALS中文题目：DZD8586在经共价或非共价BTK抑制剂及BTK降解剂治疗后的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的I/II期研究英文题目：Phase 1/2 Studies of DZD8586 in CLL/SLL Patients after Covalent or Non-covalent BTKInhibitors and BTK Degraders摘要号：146发言人：南京医科大学第一附属医院（江苏省人民医院）李建勇教授时间：6.19 17:35地点：Auditorium, West Campus USI7NK/T细胞淋巴瘤NK/T-CELL LYMPHOMA中文题目：SHR2554（一种口服性EZH2抑制剂）在复发或难治性外周T细胞淋巴瘤中的关键性研究英文题目：A Pivotal Study of SHR2554, An Oral Inhibitor Against Enhancer of Zeste Homolog 2 (EZH2), in Relapsed or Refractory (r/r) Peripheral T-cell Lymphoma (PTCL)摘要号：61发言人：北京大学肿瘤医院宋玉琴教授时间：6.20 09 :15地点：Room B,broadcast in Marquee Parco Ciani中文题目：帕博利珠单抗联合放疗治疗新诊断早期自然杀伤/T细胞淋巴瘤虚弱患者的Ⅱ期临床试验（IELSG50）英文题目：A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)摘要号：62发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.20 09 :30地点：Room B,broadcast in Marquee Parco Ciani中文题目：卡瑞利珠单抗联合低剂量阿帕替尼及培门冬酶后行放疗治疗新诊断Ⅰ/Ⅱ期自然杀伤/T细胞淋巴瘤：一项多中心Ⅱ期研究英文题目：Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study摘要号：63发言人：Chuanxu Liu（上海）时间：6.20 09 :45地点：Room B,broadcast in Marquee Parco Ciani8淋巴瘤研究：来自中国与欧洲的最新进展LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE中文题目：弥漫性大B细胞淋巴瘤治疗进展：中国视角亮点英文题目：Advances in DLBCL Management: Highlights from China摘要号：UCLI1发言人：哈尔滨血液病肿瘤研究所赵东陆教授时间：6.20 14:35地点：Polivalente room,East Campus USI中文题目：液体活检技术在淋巴瘤领域的最新进展英文题目：State-of-the-art of Liquid Biopsy in Lymphoma摘要号：UCLI3发言人：Meng Wu（北京）时间：6.20 14:55地点：Polivalente room,East Campus USI中文题目：中国新型药物在惰性淋巴瘤治疗中的国际应用概述英文题目：International Overview of Chinese Novel Drugs in Indolent Lymphoma摘要号：UCLI5发言人：吉林大学白求恩第一医院白鸥教授时间：6.20 16:15地点：Polivalente room,East Campus USI9新型药物NEW DRUGS中文题目：一项评估选择性 EZH2 抑制剂-XNW5004 在复发/难治性非霍奇金淋巴瘤受试者中安全性和有效性的 1/2 期研究英文题目：A Phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/ refractory non-Hodgkin lymphoma摘要号：95发言人：中国医学科学院血液病医院（中国医学科学院血液学研究所）邱录贵教授时间：6:21 10:30地点：Room A10T细胞淋巴瘤的生物学与治疗BIOLOGY AND THERAPY OF T-CELL LYMPHOMAS中文题目：他泽司他联合Amdizalisib 治疗具有不同基因组特征的复发或难治性外周T细胞淋巴瘤患者：一项Ⅱ期研究结果英文题目：Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study摘要号：163发言人：上海交通大学医学院附属瑞金医院程澍教授时间：6:21 09:55地点：Room B中文题目：林普利塞联合CHOP方案治疗新诊断外周T细胞淋巴瘤：一项单臂、开放标签、多中心Ⅰb/Ⅱ期研究（LINCH试验）英文题目：Linperlisib Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma: A Single-Arm,Open-Lable, Multi-Center Phase Ib/II Study (LINCH Trial)摘要号：165发言人：中山大学附属肿瘤医院蔡清清教授时间：6.21 10:15地点：Room B中文题目：戈利昔替尼（一种选择性JAK1抑制剂）作为一线全身治疗后外周T细胞淋巴瘤患者维持治疗的疗效更新：Ⅱ期研究（JACKPOT26）进展英文题目：Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with PTCLs after First-line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)摘要号：167发言人：浙江大学医学院附属第一医院金洁教授时间：6.21 10:35地点：Room B壁报展示（POSTER）1淋巴瘤生物学Lymphoma biology中文题目：稳定化MYCT58A突变绕过T细胞辅助作用驱动生发中心B细胞淋巴瘤发生英文题目：Stabilized MYCT58A Bypasses T-Cell Help to Fuel Germinal Center B-Cell Lymphomagenesis摘要号：171作者：Baizhi Chen2淋巴瘤遗传学Lymphoma genetics中文题目：EGR2基因突变预示接受布鲁顿酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者预后不良英文题目：EGR2 mutations Confer Poor Prognosis in Chronic Lymphocytic Leukemia Treated with Bruton Tyrosine Kinase Inhibitors摘要号：176作者：Huayuan Zhu中文题目：结外受累滤泡性淋巴瘤的临床特征与分子异质性分析英文题目：Clinical characteristics and molecular heterogeneity in Follicular Lymphoma with extranodal involvement摘要号：178作者：赵维莅3淋巴瘤分类Lymphoma classification中文题目：全基因组测序揭示三种具有不同起源细胞特征和患者预后的滤泡性淋巴瘤亚型英文题目：Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell-of-origin and patient outcomes摘要号：193作者：Weicheng Ren中文题目：多组学解析EB病毒驱动的结外NK/T细胞淋巴瘤进展中的异质性、代谢重塑及肿瘤细胞图谱英文题目：Multi-omics dissection of EBV-driven heterogeneity, metabolic remodeling, and tumor cellular landscape in ENKTL progression摘要号：195作者：梁金花4慢性淋巴细胞白血病Chronic lymphocytic leukemia中文题目：癌前生发中心B细胞的免疫监视机制研究英文题目：Immunosurveillance of Precancerous Germinal Center B Cells摘要号：202作者：LINGLING ZHANG中文题目：空间组学与单细胞多组学揭示原发性中枢神经系统淋巴瘤与弥漫大B细胞淋巴瘤的巨噬细胞异质性英文题目：Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary CNS Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)摘要号：206作者：Liang Hong5边缘区与淋巴浆细胞性淋巴瘤Marginal zone and lymphoplasmacytic lymphoma中文题目：奥布替尼联合奥妥珠单抗（O2方案）一线治疗边缘区淋巴瘤的疗效、安全性及合理性：前瞻性队列研究英文题目：The efficacy, safety and rationality of Orelabrutinib plus Obinutuzumab (O2) in systemic treatment-naïve marginal zone lymphoma: a prospective cohort study摘要号：255作者：Jiadai Xu6套细胞淋巴瘤Mantle Cell Lymphoma中文题目：非结节性套细胞淋巴瘤未必等同于惰性MCL：LEO队列研究的临床观察英文题目：Leukemic non-nodal mantle cell lymphoma (nnMCL) is not necessarily equivalent to indolent MCL: A report from the LEO Cohort Study.摘要号：271作者：Tony Zibo Zhuang7侵袭性B细胞淋巴瘤——一线临床试验Aggressive B-cell lymphomas-first line clinical trials中文题目：新型ZCR方案（泽布替尼、西达本胺、利妥昔单抗）±CHOP方案在双表达弥漫大B细胞淋巴瘤一线治疗中展现显著疗效英文题目：Novel ZCR (Zanubrutinib, Chidamide, Rituximab) ± CHOP Regimen Demonstrates Promising Efficacy in Frontline Treatment of Double-Expressor Diffuse Large B-Cell Lymphoma摘要号：284作者：Zhiming Li中文题目：维泊妥珠单抗、泽布替尼联合利妥昔单抗（Pola-ZR方案）治疗初治老年及虚弱DLBCL患者的疗效与安全性：前瞻性Ⅱ期临床试验英文题目：Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial摘要号：285作者：Yuhong Ren8侵袭性B细胞淋巴瘤治疗结果Aggressive B-cell lymphomas outcomes中文题目：POLARIX研究5年亚组分析：亚洲未经治疗的DLBCL患者中Pola-R-CHP方案的疗效获益验证英文题目：Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study摘要号：288作者：宋玉琴中文题目：中国大规模真实世界研究：不同基因亚型弥漫大B细胞淋巴瘤的临床实践模式与预后差异英文题目：Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China摘要号：294作者：许彭鹏9复发/难治性侵袭性B细胞淋巴瘤：临床试验Relapsed/refractory aggressive B-cell lymphomas: clinical trials中文题目：分子亚型指导的R-MINE+X方案治疗复发/难治性弥漫大B细胞淋巴瘤：单臂开放标签多中心Ⅱ期研究英文题目：Molecular Subtype-Guided R-MINE+X Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-arm, Open-label, Multicenter Phase II Study摘要号：317作者：梁金花10中枢神经系统淋巴瘤CNS Lymphomas中文题目：MEDZ-R方案治疗新诊断原发性中枢神经系统淋巴瘤的多中心前瞻性Ⅱ期临床试验英文题目：A multi-center prospective phase II clinical trial of the MEDZ-R regimen for the treatment of newly diagnosed primary central nervous system lymphoma摘要号：332作者：li Zou中文题目：利妥昔单抗联合大剂量甲氨蝶呤及奥布替尼作为新诊断原发性中枢神经系统淋巴瘤的诱导治疗方案英文题目：Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma摘要号：333作者：Wenrong Huang中文题目：奥布替尼联合抗PD-1抗体与福莫司汀治疗新诊断原发性中枢神经系统淋巴瘤的Ⅰ/Ⅱ期研究英文题目：A Phase I/II Study of Orelabrutinib Combined with Anti-PD-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)摘要号：334作者：Wanyue Zhao11原发性纵隔淋巴瘤Primary mediastinal lymphoma中文题目：替雷利珠单抗联合R-CHOP方案治疗初治原发性纵隔大B细胞淋巴瘤：前瞻性Ⅱ期临床试验英文题目：Anti-PD-1 antibody (Tislelizumab) combined with R-CHOP for the treatment of previously untreated primary mediastinal B-cell lymphoma: A prospective phase II study摘要号：347作者：Wen Shu juan12霍奇金淋巴瘤Hodgkin Lymphoma中文题目：老年霍奇金淋巴瘤治疗格局演变与预后分析：中国15年多中心回顾性研究揭示新型疗法影响英文题目：Evolving Treatment Landscape and Outcomes in Elderly Hodgkin Lymphoma: A 15-Year Multicenter Retrospective Analysis from China Highlighting the Impact of Novel Therapies摘要号：366作者：赵培起13儿科淋巴瘤Pediatric lymphomas中文题目：中国南方真实世界研究：PD-1抗体单药及联合方案治疗儿童淋巴瘤的疗效与安全性英文题目：real world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients in South China摘要号：375作者：Jia Zhu中文题目：儿童、青少年及青年霍奇金淋巴瘤长期生存者的晚期并发症与生活质评估英文题目：Late Complications and Quality of Life in Long-Term Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma摘要号：377作者：Linnan Wu14NK/T细胞淋巴瘤NK/T-cell Lymphomas中文题目：EGF-JAK/STAT通路突变对血管免疫母细胞性T细胞淋巴瘤的预后及功能影响研究英文题目：Prognostic and Functional Impact of EGF-JAK/STAT Pathway Mutations in Angioimmunoblastic T-cell Lymphoma (AITL)摘要号：384作者：DACHUAN HUANG中文题目：全血EB病毒DNA载量在血管免疫母细胞性T细胞淋巴瘤中的预后价值分析英文题目：The prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma摘要号：385作者：Yi Zhong中文题目：阿扎胞苷联合西达本胺及CHOP方案对比CHOP方案治疗初治外周T细胞淋巴瘤的Ⅱ期研究英文题目：A phase II study of azacitidine and chidamide plus CHOP versus CHOP in previously untreated patients with peripheral T-cell lymphoma摘要号：391作者：Chong Wei中文题目：西达本胺联合阿扎胞苷、米托蒽醌脂质体及泼尼松（CAMP方案）治疗TFH来源的初治外周T细胞淋巴瘤英文题目：Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma摘要号：392作者：Huimin Liu中文题目：PD-1抑制剂信迪利单抗联合培门冬酶与安罗替尼治疗Ⅳ期NK/T细胞淋巴瘤的疗效与安全性：多中心前瞻性研究英文题目：A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody Sintilimab in Combination With Pegaspargase and Anlotinib in Stage IV NKTCL Patients摘要号：400作者：Rong Tao15多发性骨髓瘤Multiple Myeloma中文题目：塞利尼索联合硼替佐米、来那度胺及地塞米松治疗高危初治多发性骨髓瘤的单臂多中心观察性研究英文题目：A single-arm, multi-center, observational study of Selinexor combined bortezomib, lenalidomide, and dexamethasone in high-risk newly diagnosed multiple myeloma(NDMM) 摘要号：403作者：Yuping Zhong16液体活检Liquid Biopsy中文题目：动态ctDNA监测揭示的分子特征：不同基因亚型弥漫大B细胞淋巴瘤的预后价值、临床病程及克隆演化规律英文题目：Molecular features encoded in the dynamic ctDNA monitoring reveal prognostic value, different clinical courses and clone evolution for different genetic subtypes of DLBCL摘要号：422作者：梁金花17新型组合Novel compounds中文题目：泽布替尼联合来那度胺治疗复发/难治性弥漫大B细胞淋巴瘤的Ⅰ期临床研究分析英文题目：Analysis of a Phase 1 Study of Zanubrutinib (Zanu) + Lenalidomide (Len) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)摘要号：439作者：张会来18新型细胞疗法New cellular therapies中文题目：携带OX40信号的CAR-T疗法驱动CD4+T细胞克隆扩增并克服B细胞淋巴瘤免疫抑制微环境：Ⅰ期临床试验英文题目：CAR-T Therapy with OX40 Signaling Drives Clonal Expansion of CD4+ T Cells and Overcomes Immunosuppressive Microenvironment in B-Cell Lymphoma: A Phase I Trial摘要号：466作者：Ling-Shuang Sheng*因官网尚未公布详细壁报信息，可能出现错漏，敬请谅解《肿瘤瞭望-血液时讯》将全程追踪并深度解析18-ICML的学术动态与会议进展，诚邀广大血液肿瘤领域临床工作者及研究人员持续关注本刊后续报道！（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

放射疗法临床2期

2025-04-30

·医药速览

Science子刊：抑制DNMT1，给T细胞（CAR-T）增加NK细胞功能，显著增强抗肿瘤活性

T细胞和NK细胞杀伤肿瘤功能不相同，如果把NK细胞的功能添加到T细胞上，或者CART细胞上，能不能让T杀伤癌细胞能力增强呢？3月21日，《Science Immunology》一篇标题为：DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity 的文章，研究了DNMT1（DNA甲基转移酶1）在维持T细胞特性和抑制其向自然杀伤(NK)样细胞转变中的关键作用。通过抑制DNMT1，研究人员成功将T细胞（包括CAR-T细胞）重编程为具有增强抗肿瘤活性的NK样细胞，体外体内杀伤肿瘤能力显著增强。此前研究表明，转录因子BCL11B的失活可以将T细胞重编程为诱导型T到NK细胞（ITNKs），展现出抗肿瘤活性。然而，BCL11B是如何抑制自然杀伤（NK）细胞转录程序的分子机制尚不清楚。蛋白质组学分析发现，BCL11B在T细胞中与DNMT1和UHRF1形成复合物，共同维持DNA甲基化状态。这一表观遗传机制对抑制NK细胞相关基因的表达至关重要。敲除DNMT1或UHRF1会导致T细胞中NK细胞标志物NKp30和NKp46的显著上调，表明UHRF1-DNMT1轴在维持T细胞特性方面的重要作用。使用非核苷类DNMT1选择性抑制剂GSK3484862（GSK862）处理CD4和CD8 T细胞后，这些细胞表现出NK细胞特征，包括NKp30和NKp46的表达上调。类似地，FDA批准的泛DNMT抑制剂地西他滨（DAC）也能在原代人T细胞中诱导NK细胞标志物的表达。这些结果表明，通过化学手段干预DNMT1/UHRF1轴，可以有效模拟BCL11B缺失的效应，为T细胞重编程提供了一种高效且可控的策略。敲除DNMT1或UHRF1以及使用GSK862处理的T细胞在UMAP空间中形成独特的细胞簇，这些细胞表现出NK细胞标志物（如NKp30、NKp46）的上调和T细胞特异性转录因子TCF7的下调，同时还显著增加了杀伤细胞免疫球蛋白样受体（KIRs）家族成员（如KIR3DL1、KIR2DL2/L3/S2、KIR2DS1）和NKp44的表达。此外，DNMT1抑制上调了CD94和NKG2A，但未诱导NK细胞激活受体NKG2C或ADCC相关受体CD16的表达。部分NK细胞相关基因（如SIGLEC7、TYROBP、KIR家族成员）在DNMT1/UHRF1抑制组中显著上调，而在BCL11B缺失组中无明显变化，而另一些基因（如IL18R1、NCAM1、ZNF683）则更倾向于在BCL11B缺失时上调。这些数据表明，抑制维持性DNA甲基化和敲除BCL11B虽然都能诱导T细胞向NK样细胞转化，但两者调控的基因网络存在显著差异，展现了共享和独特的转录特征。抑制DNMT1生成的NK样细胞展现出比BCL11B缺失ITNKs更强的细胞毒性，可能归因于其分泌更高水平的干扰素-γ（IFN-γ）、颗粒酶A/B、颗粒溶素和穿孔素。抗体阻断实验进一步证实，NKp30和NKp46在NK样细胞对K562细胞的杀伤中起关键作用。这些NK样细胞能够通过NCRs和TCRs识别多种癌细胞系，例如有效裂解表达OKT3的NALM6细胞，而对野生型NALM6无显著作用。这表明，DNMT1抑制重编程的NK样细胞兼具天然免疫和适应性免疫的双重识别能力。NK样细胞在体内展现优异抗肿瘤活性，并可通过CAR工程化增强特异性。在免疫缺陷NSI小鼠模型中评估了NK样细胞对HepG2和K562异种移植瘤的抗肿瘤效果。结果显示，与BCL11B缺失ITNKs相比，由DNMT1抑制或GSK862处理生成的NK样细胞在两种模型中均更显著地抑制肿瘤生长并延长小鼠生存期。肿瘤浸润的NK样细胞高表达活化标志物CD69，而PD1和LAG3的表达水平低于对照组。体外扩增和再刺激后，这些细胞分泌更高水平的颗粒酶B和颗粒溶素。为提高肿瘤识别特异性，研究将抗CD19或抗间皮素（MSLN）CAR转导入GSK862处理的NK样细胞中，结果表明这些CAR-NK样细胞在体内外均展现出优于传统CAR-T细胞的抗肿瘤活性。这些数据证明，DNMT1抑制重编程的NK样细胞不仅具备强效抗肿瘤能力，还可通过CAR工程化实现靶向治疗，进一步增强其临床应用潜力。DNMT1的非酶功能通过稳定BCL11B抑制T细胞向NK样细胞重编程。研究发现，DNMT1与BCL11B相互作用，并通过其非酶功能维持BCL11B的蛋白稳定性，从而支持T细胞特性。DNMT1-BCL11B相互作用在抑制T细胞向NK样细胞重编程中的关键作用。GSK862处理显著上调CD4和CD8 T细胞中NKp30和NKp46的表达，但外源性过表达BCL11B能够部分逆转这一效应。这表明，DNMT1通过与BCL11B的物理相互作用维持其稳定性，从而抑制T细胞向NK样细胞的转化。进一步发现，抑制DNMT1和EZH2可协同重编程T细胞，增强NK样细胞的生成和抗肿瘤活性。DNA甲基化和H3K27me3共同抑制NK细胞相关基因的表达，而联合使用DNMT1抑制剂（如GSK862）和EZH2抑制剂（如EPZ6438）可显著解除这种抑制，促进NK细胞特异性基因的表达和染色质开放性。这种协同作用通过激活NK细胞相关信号通路（如细胞毒性因子和免疫调控基因）实现，从而提升T细胞向NK样细胞的转化效率及其抗肿瘤功能。这些结果表明，DNA甲基化和H3K27me3是防止T细胞转变为NK样细胞的双重保障机制。最后，这项研究揭示了DNMT1在维持T细胞特性和抑制NK细胞程序中的关键分子机制，并提出了通过使用表观遗传抑制剂（特别是DNMT1抑制剂，以及与EZH2抑制剂联合使用）将T细胞转化为具有增强抗肿瘤活性的NK样细胞的新策略，为癌症免疫治疗提供了新的思路和潜在的细胞来源。参考资料：Yao Li et al. ,DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity.Sci. Immunol.10,eadm8251(2025).DOI:10.1126/sciimmunol.adm8251推文用于传递知识，如因版权等有疑问，请于本文刊发30日内联系医药速览。原创内容未经授权，禁止转载至其他平台。有问题可发邮件至yong_wang@pku.edu.cn获取更多信息。©2021 医药速览保留所有权利往期链接“小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学| 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普|医药前沿笔记PROTAC技术| 抗体药物| 抗体药物偶联-ADC核酸疫苗 | CAR技术| 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群加作者微信（yiyaoxueshu666）或者扫描公众号二维码添加作者，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

细胞疗法免疫疗法临床研究

100 项与氢溴酸他泽司他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11485	氢溴酸他泽司他	L01	DB12887

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
滤泡性淋巴瘤	美国	Epizyme, Inc.	2020-06-18
肉瘤	美国	Epizyme, Inc.	2020-01-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性滤泡性淋巴瘤	临床3期	美国	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	中国	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	澳大利亚	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	比利时	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	加拿大	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	法国	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	德国	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	匈牙利	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	意大利	Epizyme, Inc.	2020-06-11
难治性滤泡性淋巴瘤	临床3期	波兰	Epizyme, Inc.	2020-06-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02601950 (CTgov)	临床2期	典型的畸胎样横纹肌样瘤 \| 脊索瘤 \| 肾髓样癌 ... 更多	267	tazemetostat (Rhabdoid Tumors: Cohort 1)	選夢壓夢齋範壓淵遞艱 = 製窪醖範製蓋齋鏇醖選鹹積製構繭艱夢壓艱獵 (夢積鑰衊膚艱壓遞願艱, 膚鑰顧鑰鹹鬱觸觸築鬱 ~ 繭築鏇積艱積窪顧淵願) 更多	-	2025-03-11
				tazemetostat (Other INI1-negative: Cohort 3)	選夢壓夢齋範壓淵遞艱 = 獵壓築衊壓繭觸壓醖淵鹹積製構繭艱夢壓艱獵 (夢積鑰衊膚艱壓遞願艱, 顧簾壓餘獵構觸範糧繭 ~ 簾製憲淵顧構壓簾鏇構) 更多
NCT03348631 (CTgov)	临床2期	复发性卵巢透明细胞腺癌 \| 子宫内膜样腺癌 \| 复发性卵巢癌 ... 更多	62	Tazemetostat (Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients)	衊鹹獵齋構遞廠遞顧醖 = 鹽繭壓顧網網淵獵遞鹽醖鏇襯鹹願廠範簾廠窪 (鹽遞蓋鏇構夢繭製鹽糧, 鑰繭壓夢膚願網廠淵鹽 ~ 鬱鹹願鬱壓憲獵範淵選) 更多	-	2025-03-06
				Tazemetostat (Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients)	衊鹹獵齋構遞廠遞顧醖 = 膚餘獵構積築製襯廠夢醖鏇襯鹹願廠範簾廠窪 (鹽遞蓋鏇構夢繭製鹽糧, 襯繭醖夢鬱選願獵蓋廠 ~ 鬱醖淵餘廠網齋鹽夢簾) 更多
ASH2024	N/A	滤泡性淋巴瘤	-	Tazemetostat 800mg BID	遞淵顧鹹齋鹹鑰顧願遞(衊壓選簾顧範鹹繭鹽艱) = leukopenia (n=2), neutropenia (n=1), anemia (n=1), atrial fibrillation (n=1), bone pain (n=1), infection (n=2), and infusion related reaction (n=1) 鬱鑰鹹廠鏇積鹹構醖壓 (衊範衊艱襯築築鹽鬱憲 ) 更多	-	2024-12-09
NCT04179864 (EZH-1101, ESMO2024) 人工标引	临床1/2期	转移性去势抵抗性前列腺癌	81	TAZ 1200 mg BID plus ENZ 160 mg QD	構壓願襯鏇鑰製齋糧觸(鹽糧艱鹽選築獵艱願鹹) = 蓋醖襯醖繭襯網夢衊鏇艱膚顧鹽廠繭廠選窪壓 (繭鑰繭糧獵顧蓋膚齋構, 8.5 ~ NE) 更多	不佳	2024-09-15
				ENZ 160 mg QD	構壓願襯鏇鑰製齋糧觸(鹽糧艱鹽選築獵艱願鹹) = 憲選鑰簾醖顧鹹鹽簾製艱膚顧鹽廠繭廠選窪壓 (繭鑰繭糧獵顧蓋膚齋構, 6.6 ~ NE) 更多
NCT04537715 (CTgov)	临床1期	肾髓样癌 \| 滤泡性淋巴瘤 \| 横纹样瘤 ... 更多	42	Tazemetostat (Part 1: Tazemetostat)	鹹製醖願顧繭鬱鬱積繭(醖夢壓顧範鏇鏇齋鹽蓋) = 餘糧築夢鬱糧膚遞築糧壓顧衊選襯衊餘蓋簾觸 (網鬱繭遞築糧糧鬱襯衊, 55.3) 更多	-	2024-08-26
				Tazemetostat (Part 2: Tazemetostat)	窪製積構鑰鏇構構製鏇(網淵積構積築蓋獵製衊) = 廠鬱構鬱鑰獵艱窪遞觸鹹觸願齋蓋膚壓選積餘 (願廠夢醖醖遞遞糧觸衊, 83.2) 更多
NCT03854474 (ETCTN 10183, ASCO2024)	临床1/2期	晚期尿路上皮癌 COMPASS-related proteins KMT2D \| KMT2C \| KDM6A ... 更多	-	Tazemetostat 800 mg BID + Pembrolizumab 200 mg	齋繭淵鑰淵糧廠簾築衊(醖憲襯壓廠憲壓遞窪顧) = 繭簾憲顧鬱積蓋獵艱蓋鑰衊蓋糧窪膚夢衊築鏇 (蓋築鹽蓋壓齋淵積壓膚 ) 更多	-	2024-05-24
				Pembrolizumab 200 mg	齋繭淵鑰淵糧廠簾築衊(醖憲襯壓廠憲壓遞窪顧) = 製餘構簾齋淵積鹽夢願鑰衊蓋糧窪膚夢衊築鏇 (蓋築鹽蓋壓齋淵積壓膚 ) 更多
NCT05372354 (CA057-003, EHA2024) 人工标引	临床1/2期	多发性骨髓瘤 PRC2 Loss of Function Mutation \| EZH2 Overexpression	10	MEZI+TAZ+DEX 0.3mg	壓築鑰鏇蓋醖顧齋網廠(夢選艱衊繭衊鏇選餘網) = 觸襯顧築製壓齋鹹淵鏇選齋淵艱繭鹹製觸獵淵 (夢窪壓淵獵觸鏇鬱觸糧 ) 更多	积极	2024-05-14
NCT05713110 (EHA2024)	临床2期	淋巴瘤	21	Tazemetostat 800mg BID	鏇窪顧簾壓糧鏇憲繭鹽(鏇獵夢觸鹽願鑰築鬱齋) = 4 pts, 19.0% 鹹繭艱選廠憲鹽願膚遞 (艱構壓簾膚蓋廠膚壓鹽 ) 更多	积极	2024-05-14
				Amdizalisib 30mg QD
NCT04224493 (SYMPHONY-1, ASH2023)	临床3期	难治性滤泡性淋巴瘤	815	Tazemetostat plus Lenalidomide and Rituximab	膚鏇鑰製鹽鏇糧餘獵築(築構簾鏇醖範構醖鏇壓) = 簾夢醖醖鹽夢糧顧鏇糧簾鑰廠壓鏇艱鏇鏇構築 (鑰鏇餘簾廠糧衊網顧觸 )	积极	2023-12-11
				Lenalidomide and Rituximab	膚鏇鑰製鹽鏇糧餘獵築(築構簾鏇醖範構醖鏇壓) = 鹹獵餘積壓糧廠簾窪艱簾鑰廠壓鏇艱鏇鏇構築 (鑰鏇餘簾廠糧衊網顧觸 )
ASH2023	临床2期	滤泡性淋巴瘤	62	Tazemetostat 800mg BID + R-CHOP	襯顧製艱獵遞齋網鑰餘(艱顧簾繭鬱觸餘鹽繭襯) = 淵鏇淵醖壓顧糧蓋鏇鑰淵廠衊獵糧積膚獵製鏇 (襯餘觸選鹹觸憲鑰遞鹹 ) 更多	-	2023-12-09